Seven months after the launch of the experimentation with cannabis for medical use by the Ministry of Health, 1,000 patients were included and more than 1,000 health professionals are mobilized throughout France, indicates a press release from the National Medicines Safety Agency (ANSM) and the General Directorate of Health (DGS). Among the five indications retained in the context of the experiment, the most represented in the people included are refractory neuropathic pain, painful spasticity in multiple sclerosis and certain forms of drug-resistant epilepsy. “We know that medical cannabis will not be the solution for everyone, but if we manage to relieve a certain number of patients who have so far failed to treat treatment, we will have won part of the fight”, testifies Mado Gilanton, member of the ANSM expert committee and president of the Apaiser S&C association. Of the 1,000 people, 779 are currently being followed, some having quit the experiment due in particular to adverse effects or ineffectiveness. “Defining the most effective and best tolerated dose possible by patients is one of the clinical challenges of this experiment. This is why the construction of a therapeutic alliance between the patient and the healthcare professional is essential. Medical cannabis could represent a real opportunity for certain patients who suffer intensely without effective treatment, ”explains Nicolas Authier, president of the temporary scientific committee for monitoring the ANSM experiment, quoted in the press release. Among the 1,035 health professionals who have followed and validated the compulsory training prior to their participation, 775 work within the reference structures, 48 are liberal general practitioners and 212 community pharmacists. At the same time, new reference structures have volunteered, going from 202 structures in March 2021 to 243 today.